AxoGen, Inc. reiterated revenue guidance for the year 2023. The company reiterated its full year guidance with 2023 revenue in the range of $154 million to $159 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.64 USD | -2.43% | +9.61% | +11.86% |
28/05 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
16/05 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.86% | 334M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Axogen, Inc. Reiterates Revenue Guidance for the Year 2023